Envestnet Portfolio Solutions Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,217 shares of the medical research company's stock after selling 2,779 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in IQVIA were worth $2,008,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in IQV. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares during the period. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter valued at $33,000. Meeder Asset Management Inc. boosted its holdings in IQVIA by 353.7% in the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company's stock valued at $58,000 after purchasing an additional 191 shares during the last quarter. Versant Capital Management Inc grew its position in IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in shares of IQVIA during the 4th quarter valued at about $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
IQVIA Price Performance
IQV traded down $5.04 on Tuesday, reaching $181.07. 1,566,007 shares of the company's stock were exchanged, compared to its average volume of 1,239,209. The stock has a market cap of $31.93 billion, a PE ratio of 24.14, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $254.54. The stock's fifty day moving average price is $194.58 and its 200-day moving average price is $207.73.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Wall Street Analysts Forecast Growth
IQV has been the topic of several analyst reports. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, Citigroup lowered their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.
Check Out Our Latest Report on IQVIA
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
